Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Cardinal Health, Inc.    CAH

CARDINAL HEALTH, INC.

(CAH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
55.74(c) 55.99(c) 55.4(c) 55.39(c) 55.44(c) Last
1 271 461 1 277 892 994 185 1 681 250 1 257 991 Volume
-0.30% +0.45% -1.05% -0.02% +0.09% Change
More quotes
Financials (USD)
Sales 2021 161 B - -
Net income 2021 1 381 M - -
Net Debt 2021 2 949 M - -
P/E ratio 2021 12,3x
Yield 2021 3,58%
Sales 2022 168 B - -
Net income 2022 1 425 M - -
Net Debt 2022 1 801 M - -
P/E ratio 2022 11,4x
Yield 2022 3,67%
Capitalization 16 267 M 16 267 M -
EV / Sales 2021 0,12x
EV / Sales 2022 0,11x
Nbr of Employees 48 000
Free-Float 89,7%
More Financials
Company
Cardinal Health is specialized in the distribution of products and health services to pharmacies, hospitals and medical practices. Net sales break down by activity as follows: - distribution of pharmaceutical products (88.6%); - distribution of medical, surgical and laboratory products (11.4%). The group also develops a manufacturing of medical and surgical products activity (masks, overalls, gloves, diagnostic... 
More about the company
Notations Surperformance© of Cardinal Health, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about CARDINAL HEALTH, INC.
01/08CARDINAL HEALTH : Wolfe Research Upgrades Cardinal Health to Peer Perform From U..
MT
01/07CARDINAL HEALTH : celebrates 50th anniversary, launches year of service
PU
01/05CARDINAL HEALTH : launches TotalVue™ Analytics, a logistics management too..
PR
01/04CARDINAL HEALTH : to Webcast Discussion of Second-Quarter Results for Fiscal Yea..
PR
2020CARDINAL HEALTH, INC. : Ex-dividend day for
FA
2020U.S. sues Walmart saying pharmacies fueled opioid crisis, retailer rejects al..
RE
2020CARDINAL HEALTH : Picked By Ohio For COVID-19 Vaccine Distribution
MT
2020CARDINAL HEALTH : Ohio Chooses Cardinal Health for COVID-19 Vaccine Distribution
PR
2020INSIDER TRENDS : Cardinal Health Insider Makes Tax Sale Interrupting 90-Day Buy ..
MT
2020Stocks End Lower on Slowing Retail Sales Data, New Pandemic-Related Restricti..
MT
2020Amazon launches online pharmacy in new contest with drug retail
RE
2020INSIDER TRENDS : Cardinal Health Insider Makes Shares Sale for Tax Slowing 90-Da..
MT
2020Mizuho Adjusts Cardinal Health's Price Target to $59 From $56, Maintains Neut..
MT
2020Cardinal Health Reaches Agreement With CDC to Support Pharmacies' Access to C..
MT
2020CARDINAL HEALTH : Partners with CDC to Support Vaccine Access for Pharmacies
PR
More news
News in other languages on CARDINAL HEALTH, INC.
2020La justice américaine accuse Walmart d'avoir alimenté la crise des opiacés
2020CRISE DES OPIACÉS : le géant Walmart attaque le ministère américain de la Justic..
2020WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2020Ramelow stimmte für AfD-Landtagsvize - Parlamentsrechte wahren
2020AKTIE IM FOKUS 2 : Vorsichtiger Ausblick und schwacher Markt setzen Bayer zu
More news
Analyst Recommendations on CARDINAL HEALTH, INC.
More recommendations
Chart CARDINAL HEALTH, INC.
Duration : Period :
Cardinal Health, Inc. Technical Analysis Chart | CAH | US14149Y1082 | MarketScreener
Technical analysis trends CARDINAL HEALTH, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 62,81 $
Last Close Price 55,44 $
Spread / Highest target 29,9%
Spread / Average Target 13,3%
Spread / Lowest Target -0,79%
EPS Revisions
Managers and Directors
NameTitle
Michael C. Kaufmann Chief Executive Officer & Director
Gregory B. Kenny Independent Non-Executive Chairman
Jason M. Hollar Chief Financial Officer
Brian S. Rice Chief Information Officer & Executive VP
J. Michael Losh Independent Director
Sector and Competitors